Akari TX

NEW YORK and LONDON, March 8, 2022 – Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative …

[Read more...] about Akari Therapeutics, Plc Announces $9.0 Million Registered Direct Offering

Industry veteran brings extensive experience in the development and commercialization of advanced biological therapies, including in the field of …

[Read more...] about Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer

Akari’s complement and leukotriene inhibitor, nomacopan, demonstrated improved survival (80% vs. 30%) in a preclinical model of traumaA follow-on program …

[Read more...] about Akari Therapeutics Announces New Data Showing A Significant Role for Complement Activation in the Clinical Outcomes of U.S. Army Trauma Patients in Iraq and the Therapeutic Potential of Nomacopan for Treatment of Trauma

NEW YORK and LONDON, February 11, 2022 – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to …

[Read more...] about Akari Therapeutics to Present at BIO CEO & Investor Conference